Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12618000664246
Ethics application status
Approved
Date submitted
12/03/2018
Date registered
24/04/2018
Date last updated
24/04/2018
Type of registration
Retrospectively registered

Titles & IDs
Public title
Studying the need of medical treatment together with removal of the testes surgically to treat men with late cancer of prostate.
Scientific title
Is Combined Androgen Blockade by Surgical Castration and Flutamide Necessary as an Initial Therapy for Patients with Advanced Prostate Cancer? A randomized clinical trial.
Secondary ID [1] 294305 0
None
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Prostate cancer 307393 0
Condition category
Condition code
Cancer 306105 306105 0 0
Prostate
Surgery 306549 306549 0 0
Surgical techniques

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Patients with advanced prostate cancer were randomized into two groups after being subjected to surgical castration by bilateral simple orchidectomy . The duration of surgery was about 30 minutes. Group I was followed up for disease progression after orchidectomy alone.Group II patients also had underwent bilateral simple orchidectomy but additionally they were given oral flutamide 250 mg tablets three times daily after meals for up to two years and were followed up. Bilateral simple Orchidectomy for both groups was done by scrotal approach under spinal anesthesia . The patients were asked to return the drug tablet to ensure adherence to the intervention.The follow up period was up to two years following orchidectomy for both groups.
Intervention code [1] 300606 0
Treatment: Other
Comparator / control treatment
Group I patients who underwent orchidectomy only was considered as the comparator reference group.
Control group
Active

Outcomes
Primary outcome [1] 305136 0
Percent change in values of PSA . Levels of PSA were assessed by serum assay for all patients.
Timepoint [1] 305136 0
One month , two month and three months following orchidectomy ( primary endpoint ) . The serum PSA was assessed at the end of first month , second month and third month following orchidectomy to detect the maximum percent change in serum PSA.
Primary outcome [2] 305505 0
Percent change in levels of serum testosterone were assessed by serum assay.
Timepoint [2] 305505 0
One month , two month and three months following orchidectomy ( primary endpoint ) . The serum testosterone was assessed at the end of first month , second month and third month following orchidectomy to detect the maximum percent change in serum testosterone.
Secondary outcome [1] 344293 0
Percent change in serum PSA at the end of second year following orchidectomy
Timepoint [1] 344293 0
This outcome will be assessed a single time at the end of the second year following orchidectomy .
Secondary outcome [2] 345512 0
This is a composite outcome by checking for disease spread to distant organs despite initiation of therapy.This was measured by detection of new metastasis in bone , liver or other organs by doing Ct scan of abdomen and bone radiology,
Timepoint [2] 345512 0
This outcome was assessed a single time at the end of the second year following orchidectomy for both groups.

Eligibility
Key inclusion criteria
Patients with advanced prostate cancer
Minimum age
55 Years
Maximum age
75 Years
Sex
Males
Can healthy volunteers participate?
No
Key exclusion criteria
patients with local disease or severe co-morbidities .

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomization by giving patients numbers at time of recruitment , then patients with odd numbers were allocated to group I and those with even numbers to group II.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Analysis of variance ( ANOVA ) was used to analyze the differences among groups mean and percentage.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
Actual
20/05/2012
Date of last participant enrolment
Anticipated
Actual
30/09/2015
Date of last data collection
Anticipated
Actual
2/10/2017
Sample size
Target
60
Accrual to date
Final
51
Recruitment outside Australia
Country [1] 9675 0
Iraq
State/province [1] 9675 0
Basrah

Funding & Sponsors
Funding source category [1] 298951 0
Hospital
Name [1] 298951 0
Basrah General Hospital
Country [1] 298951 0
Iraq
Funding source category [2] 298952 0
University
Name [2] 298952 0
Basrah University
Country [2] 298952 0
Iraq
Primary sponsor type
University
Name
Basrah university
Address
Iraq - Basrah al Bradehia St. no 10
PO. Box 953
Country
Iraq
Secondary sponsor category [1] 298164 0
None
Name [1] 298164 0
None
Address [1] 298164 0
None
Country [1] 298164 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 299888 0
Basrah college of medicine
Ethics committee address [1] 299888 0
Ethics committee country [1] 299888 0
Iraq
Date submitted for ethics approval [1] 299888 0
02/01/2012
Approval date [1] 299888 0
25/02/2012
Ethics approval number [1] 299888 0
2343

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 81874 0
A/Prof Firas Shakir Attar
Address 81874 0
Iraq -Basrah 1135 - 42001 Ashar. Basrah College of medicine .
Country 81874 0
Iraq
Phone 81874 0
+9647801642247
Fax 81874 0
Email 81874 0
firasshakir97@yahoo.com
Contact person for public queries
Name 81875 0
Firas Shakir Attar
Address 81875 0
Iraq -Basrah 1135 - 42001 Ashar. Basrah college of medicine .
Country 81875 0
Iraq
Phone 81875 0
+9647801642247
Fax 81875 0
Email 81875 0
firasshakir97@yahoo.com
Contact person for scientific queries
Name 81876 0
Firas Shakir Attar
Address 81876 0
Iraq -Basrah 1135 - 42001 Ashar. Basrah college of medicine .
Country 81876 0
Iraq
Phone 81876 0
+9647801642247
Fax 81876 0
Email 81876 0
firasshakir97@yahoo.com

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.